Gastric Cancer - Pipeline Review, H2 2016

Date: October 26, 2016
Pages: 963
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GE94D3AFA18EN
Leaflet:

Download PDF Leaflet

Gastric Cancer - Pipeline Review, H2 2016
Gastric Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H2 2016, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 68, 68, 7, 65, 6 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 3, 7 and 1 molecules, respectively for Gastric Cancer.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Gastric Cancer Overview
Therapeutics Development
Gastric Cancer - Therapeutics under Development by Companies
Gastric Cancer - Therapeutics under Investigation by Universities/Institutes
Gastric Cancer - Pipeline Products Glance
Gastric Cancer - Products under Development by Companies
Gastric Cancer - Products under Investigation by Universities/Institutes
Gastric Cancer - Companies Involved in Therapeutics Development
Gastric Cancer - Therapeutics Assessment
Drug Profiles
Gastric Cancer - Dormant Projects
Gastric Cancer - Discontinued Products
Gastric Cancer - Product Development Milestones
Appendix 935

LIST OF TABLES

Number of Products under Development for Gastric Cancer, H2 2016
Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Investigation by Universities/Institutes, H2 2016
Gastric Cancer - Pipeline by 3SBio Inc., H2 2016
Gastric Cancer - Pipeline by AB Science SA, H2 2016
Gastric Cancer - Pipeline by AbbVie Inc, H2 2016
Gastric Cancer - Pipeline by AbGenomics International, Inc., H2 2016
Gastric Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016
Gastric Cancer - Pipeline by Advaxis, Inc., H2 2016
Gastric Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016
Gastric Cancer - Pipeline by Agenus, Inc., H2 2016
Gastric Cancer - Pipeline by Almac Discovery Limited, H2 2016
Gastric Cancer - Pipeline by Alteogen Inc., H2 2016
Gastric Cancer - Pipeline by Ambrx, Inc., H2 2016
Gastric Cancer - Pipeline by Amgen Inc., H2 2016
Gastric Cancer - Pipeline by arGEN-X BV, H2 2016
Gastric Cancer - Pipeline by Asana BioSciences, LLC, H2 2016
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016
Gastric Cancer - Pipeline by Astellas Pharma Inc., H2 2016
Gastric Cancer - Pipeline by AstraZeneca Plc, H2 2016
Gastric Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016
Gastric Cancer - Pipeline by Athenex, Inc., H2 2016
Gastric Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2016
Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd., H2 2016
Gastric Cancer - Pipeline by Bayer AG, H2 2016
Gastric Cancer - Pipeline by BeiGene, Ltd., H2 2016
Gastric Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016
Gastric Cancer - Pipeline by Bionovis SA, H2 2016
Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Gastric Cancer - Pipeline by Boston Biomedical, Inc., H2 2016
Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
Gastric Cancer - Pipeline by Calithera Biosciences, Inc., H2 2016
Gastric Cancer - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016
Gastric Cancer - Pipeline by Celgene Corporation, H2 2016
Gastric Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016
Gastric Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2016
Gastric Cancer - Pipeline by Celltrion, Inc., H2 2016
Gastric Cancer - Pipeline by Celon Pharma Sp. z o.o., H2 2016
Gastric Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016
Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016
Gastric Cancer - Pipeline by Curaxys, S.L., H2 2016
Gastric Cancer - Pipeline by DAE HWA Pharmaceutical Co., Ltd., H2 2016
Gastric Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Gastric Cancer - Pipeline by Debiopharm International SA , H2 2016
Gastric Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016
Gastric Cancer - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
Gastric Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
Gastric Cancer - Pipeline by Eddingpharm, H2 2016
Gastric Cancer - Pipeline by EirGenix Inc., H2 2016
Gastric Cancer - Pipeline by Eli Lilly and Company, H2 2016
Gastric Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016
Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2016
Gastric Cancer - Pipeline by Frost Biologic, Inc., H2 2016
Gastric Cancer - Pipeline by Galena Biopharma, Inc., H2 2016
Gastric Cancer - Pipeline by Genelux Corporation, H2 2016
Gastric Cancer - Pipeline by Genentech, Inc., H2 2016
Gastric Cancer - Pipeline by Gilead Sciences, Inc., H2 2016
Gastric Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
Gastric Cancer - Pipeline by GlycoNex Inc., H2 2016
Gastric Cancer - Pipeline by Glycotope GmbH, H2 2016
Gastric Cancer - Pipeline by Green Cross Corporation, H2 2016
Gastric Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2016
Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
Gastric Cancer - Pipeline by Horizon Pharma Plc, H2 2016
Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016
Gastric Cancer - Pipeline by Ignyta, Inc., H2 2016
Gastric Cancer - Pipeline by Immunomedics, Inc., H2 2016
Gastric Cancer - Pipeline by Imugene Limited, H2 2016
Gastric Cancer - Pipeline by Incyte Corporation, H2 2016
Gastric Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2016
Gastric Cancer - Pipeline by Intezyne Technologies, Inc., H2 2016
Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2016
Gastric Cancer - Pipeline by Johnson & Johnson, H2 2016
Gastric Cancer - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016
Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Gastric Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2016
Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
Gastric Cancer - Pipeline by LegoChem Biosciences, Inc, H2 2016
Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016
Gastric Cancer - Pipeline by MacroGenics, Inc., H2 2016
Gastric Cancer - Pipeline by MaxiVAX SA, H2 2016
Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2016
Gastric Cancer - Pipeline by MedImmune, LLC, H2 2016
Gastric Cancer - Pipeline by Medivation, Inc., H2 2016
Gastric Cancer - Pipeline by Merck & Co., Inc., H2 2016
Gastric Cancer - Pipeline by Merck KGaA, H2 2016
Gastric Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H2 2016
Gastric Cancer - Pipeline by Merus NV, H2 2016
Gastric Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Gastric Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016
Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H2 2016
Gastric Cancer - Pipeline by MolMed S.p.A., H2 2016
Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016
Gastric Cancer - Pipeline by NeuClone Pty Ltd, H2 2016
Gastric Cancer - Pipeline by Novartis AG, H2 2016
Gastric Cancer - Pipeline by OBI Pharma, Inc., H2 2016
Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2016
Gastric Cancer - Pipeline by Oncobiologics, Inc., H2 2016
Gastric Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016
Gastric Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016
Gastric Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H2 2016
Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Gastric Cancer - Pipeline by Opsona Therapeutics Limited, H2 2016
Gastric Cancer - Pipeline by Panacea Biotec Limited, H2 2016
Gastric Cancer - Pipeline by Patrys Limited, H2 2016
Gastric Cancer - Pipeline by Pfizer Inc., H2 2016
Gastric Cancer - Pipeline by Pharma Mar, S.A., H2 2016
Gastric Cancer - Pipeline by Puma Biotechnology, Inc., H2 2016
Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016
Gastric Cancer - Pipeline by Rgenix, Inc., H2 2016
Gastric Cancer - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016
Gastric Cancer - Pipeline by Samumed LLC, H2 2016
Gastric Cancer - Pipeline by Sanofi, H2 2016
Gastric Cancer - Pipeline by Sequella, Inc., H2 2016
Gastric Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016
Gastric Cancer - Pipeline by Shionogi & Co., Ltd., H2 2016
Gastric Cancer - Pipeline by Simcere Pharmaceutical Group, H2 2016
Gastric Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2016
Gastric Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
Gastric Cancer - Pipeline by Supratek Pharma Inc., H2 2016
Gastric Cancer - Pipeline by SynCore Biotechnology Co., Ltd., H2 2016
Gastric Cancer - Pipeline by Synovo GmbH, H2 2016
Gastric Cancer - Pipeline by Synthon Holdings BV, H2 2016
Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
Gastric Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
Gastric Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Gastric Cancer - Pipeline by Takis S.r.l., H2 2016
Gastric Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
Gastric Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016
Gastric Cancer - Pipeline by Transgene SA, H2 2016
Gastric Cancer - Pipeline by United BioPharma, Inc., H2 2016
Gastric Cancer - Pipeline by Vaxon Biotech, H2 2016
Gastric Cancer - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016
Gastric Cancer - Pipeline by Zymeworks Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Gastric Cancer - Dormant Projects, H2 2016
Gastric Cancer - Dormant Projects (Contd..1), H2 2016
Gastric Cancer - Dormant Projects (Contd..2), H2 2016
Gastric Cancer - Dormant Projects (Contd..3), H2 2016
Gastric Cancer - Dormant Projects (Contd..4), H2 2016
Gastric Cancer - Dormant Projects (Contd..5), H2 2016
Gastric Cancer - Dormant Projects (Contd..6), H2 2016
Gastric Cancer - Dormant Projects (Contd..7), H2 2016
Gastric Cancer - Dormant Projects (Contd..8), H2 2016
Gastric Cancer - Dormant Projects (Contd..9), H2 2016
Gastric Cancer - Dormant Projects (Contd..10), H2 2016
Gastric Cancer - Dormant Projects (Contd..11), H2 2016
Gastric Cancer - Dormant Projects (Contd..12), H2 2016
Gastric Cancer - Discontinued Products, H2 2016
Gastric Cancer - Discontinued Products (Contd..1), H2 2016
Gastric Cancer - Discontinued Products (Contd..2), H2 2016
Gastric Cancer - Discontinued Products (Contd..3), H2 2016 954

LIST OF FIGURES

Number of Products under Development for Gastric Cancer, H2 2016
Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Gastric Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 962 pages
Rectal Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 107 pages
Gastric Ulcers - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 43 pages
Ureter Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 103 pages
Rectal Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 112 pages

Ask Your Question

Gastric Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: